이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

재발성/불응성 급성 골수성 백혈병 환자를 대상으로 BL-M11D1의 안전성, 내약성, 약동학 프로파일 및 예비 효능을 평가하기 위한 다기관, 공개 라벨 제1상 임상 연구

2026년 9월 21일 업데이트: SystImmune Inc.

재발성/불응성 급성 골수성 백혈병 환자를 대상으로 BL-M11D1의 안전성, 내약성, 약동학 프로파일 및 예비 효능을 평가하기 위한 다기관, 공개 라벨 제1상 임상 연구.

The objective of this study to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of BL-M11D1 in patients with relapsed/refractory acute myeloid leukemia.

연구 개요

상태

종료됨

정황

개입 / 치료

상세 설명

BL-M11D1-HM-101 is a multi-center, Phase 1 study to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of BL-M11D1 in patients with relapsed/refractory acute myeloid leukemia.

This study will be conducted in two parts (dose escalation, and dose finding). Cohort A will be dosed on Days 1, 8,15 of a continuous 28-day treatment cycle. The cohort has different dose groups. Cohort B will be dosed on Days 1, 4, 7 or 8 of a continuous 28-day treatment cycle. The cohorts have different dose groups.

연구 유형

중재적

등록 (실제)

52

단계

  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • California
      • Duarte, California, 미국, 91010
        • City of Hope
      • Los Angeles, California, 미국, 90095
        • UCLA Ronald Reagan Medical Center
    • Colorado
      • Aurora, Colorado, 미국, 80045
        • University of Colorado Anschutz Medical Campus
    • Connecticut
      • New Haven, Connecticut, 미국, 06511
        • Yale Cancer Center, Smilow Cancer Hospital at Yale New Haven
    • Florida
      • Tampa, Florida, 미국, 33612
        • Moffitt Cancer Center
    • Illinois
      • Chicago, Illinois, 미국, 60611
        • Northwestern Memorial Hospital
    • Maryland
      • Baltimore, Maryland, 미국, 21287
        • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    • Michigan
      • Grand Rapids, Michigan, 미국, 49546
        • START Midwest/The Cancer and Hematology Center
    • New Jersey
      • Hackensack, New Jersey, 미국, 07601
        • John Theurer Cancer Center-Hackensack
    • Ohio
      • Cincinnati, Ohio, 미국, 45236
        • Oncology Hematology Care Clinical Trials, LLC
      • Columbus, Ohio, 미국, 43210
        • The Ohio State University Comprehensive Cancer Center
    • Oregon
      • Eugene, Oregon, 미국, 24224
        • WVCI Oncology Associates of Oregon
      • Portland, Oregon, 미국, 97239
        • Oregon Health and Science University
    • Pennsylvania
      • Philadelphia, Pennsylvania, 미국, 19111
        • Temple Health Fox Chase Cancer Center
    • Tennessee
      • Nashville, Tennessee, 미국, 37203
        • SCRI -TriStar BMT
    • Texas
      • Houston, Texas, 미국, 77030
        • MD Anderson Cancer Center
    • Virginia
      • Fairfax, Virginia, 미국, 22031
        • Virginia Cancer Specialists
    • Washington
      • Seattle, Washington, 미국, 98109
        • Fred Hutchinson Cancer Center

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Signed the informed consent
  2. Age ≥18 years
  3. Has a life expectancy of ≥3 months
  4. Relapsed and/or refractory CD33-positive AML as determined by local pathology review that has failed initial standard of care therapy. Diagnosis of primary AML or AML secondary to myelodysplastic syndromes. Relapsed or refractory status. CD33-positive as confirmed by local flow cytometry or cytology
  5. Has an Eastern Cooperative Oncology Group performance status (ECOG PS) 0 to 2
  6. Toxicity of previous anticancer therapy has returned to Grade ≤1 as defined by NCI CTCAE V5.0, except for alopecia and endocrinopathies controlled by replacement therapy that must be Grade ≤2
  7. Has adequate liver and renal function before registration, defined as: a. Hepatic function: Total bilirubin (TBIL) ≤1.5×ULN (≤3×ULN for subjects with Gilbert's syndrome), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5×ULN b. Renal function: Creatinine clearance ≥50 mL/min (Cockcroft-Gault, Chronic Kidney Disease Epidemiology Collaboration [CKD-Epi], or Modification of Diet in Renal Disease Study [MDRD] equations)
  8. Sexually active fertile subjects and their partners must agree to use highly effective methods of contraception during the course of the study and for 7 months after the last dose of study treatment. An additional contraceptive method, such as a barrier method (eg, condom), is recommended
  9. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test at screening and must be nonlactating

Exclusion Criteria:

  1. Subjects with acute promyelocytic leukemia (APL) or chronic myelogenous leukemia in blast crisis (CML)

  2. Chemotherapy, biological therapy, immunotherapy, radical radiotherapy, major surgery, targeted therapy (including small molecule inhibitor of tyrosine kinase), and other anticancer therapy within 2 weeks) prior to the first administration; mitomycin and nitrosoureas treatment within 6 weeks prior to the first administration, or palliative radiotherapy within 2 weeks prior to the first administration

  3. Subjects with history of severe heart disease, such as symptomatic congestive heart failure (CHF) ≥ Grade 2 (CTCAE 5.0), New York Heart Association (NYHA) ≥ Grade 2 heart failure, history of transmural myocardial infarction, unstable cardiac arrhythmias or angina pectoris within 6 months before screening

  4. Subjects with prolonged QT interval (QTcF >470 msec), complete left bundle branch block, Grade 3 atrioventricular block or a history of additional risk factors for Torsades de Pointes (TdP; eg, heart failure as defined in Exclusion Criterion 3, chronic or recurrent hypokalemia that requires medical intervention, congenital long QT syndrome, family history of long QT syndrome) or any current concomitant medication known to prolong the QT/QTc interval or cause TdP

  5. Active autoimmune diseases and inflammatory diseases, such as: systemic lupus erythematosus, psoriasis requiring systemic treatment, rheumatoid arthritis, inflammatory bowel disease and Hashimoto's thyroiditis, etc., except for Type I diabetes, hypothyroidism that can be controlled only by standard of care treatment, and skin diseases that do not require systemic treatment (such as vitiligo, psoriasis)

  6. Subjects with other prior or concurrent malignancies except for basal cell carcinoma of the skin, squamous cell carcinoma of the skin and/or carcinoma in situ after adequate resection, or other malignancy treated with curative intent with as disease-free interval of at least 1 year

  7. Subjects with poorly controlled hypertension or uncontrolled hypertension by two or more antihypertensive drugs (systolic blood pressure >150 mmHg or diastolic blood pressure >100 mmHg)

  8. Subjects with active acute or chronic graft vs. host disease (aGVHD or cGVHD) should be excluded from this study. Subjects with GVHD who are receiving treatment with systemic glucocorticoids >10 mg/day equivalent of prednisone should also be excluded from the study; however, treatment with low-dose glucocorticoids (≤10 mg/day equivalent of prednisone) is permitted

  9. Subjects currently receiving immunosuppressive therapy should be excluded from this study.

  10. Clinical evidence of disseminated intravascular coagulation (DIC). Smoldering low grade DIC is allowed after discussion with the sponsor

  11. Subjects with stroke or transient ischemic attack (TIA) within 6 months before screening

  12. Subjects with a thromboembolic event (eg, deep vein thrombosis [DVT] or pulmonary embolism [PE]) within 6 months before screening except for those who are clinically stable and receiving treatment with adequate anticoagulant therapy for at least 3 weeks before screening

  13. Subjects with active central nervous system (CNS) AML will be excluded. A lumbar puncture does not need to be performed unless there is clinical suspicion of CNS involvement per investigator judgment. Concurrent therapy for CNS prophylaxis or continuation of therapy for controlled CNS AML is allowed with the approval of the sponsor

  14. Subjects with pre-existing ≥Grade 2 peripheral neuropathy

  15. Subjects with advanced/ clinically significant lung diseases, such as poorly controlled COPD and asthma, restrictive lung disease, pulmonary hypertension etc.

  16. Subjects who have a history of noninfectious interstitial lung disease (ILD)/ pneumonitis that required treatment with steroids, have current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening

  17. Subjects who have a history of anaphylaxis or severe hypersensitivity to recombinant humanized antibodies or human-mouse chimeric antibodies or any of the components of BL-M11D1

  18. Subjects with known human immunodeficiency virus infection (HIV Ab positive) Subjects are allowed to participate if all of the following criteria are met: (1) Undetectable HIV RNA and CD4 count ≥350 cells/μL at screening, (2) No AIDS defining opportunistic infection within 12 months prior to screening, (3) On stable antiretroviral therapy (ART) for at least 4 weeks prior to screening with projected continuation of ART as clinically indicated while on the study

  19. Subjects with active Hepatitis B virus (HBV) infection (positive HBsAg test). Subjects with chronic inactive HBV infection are eligible if they meet all of the following criteria:

    1. Have a HBV DNA viral load ≤ 500 IU/mL
    2. Have normal AST and ALT, OR if liver involvement is present, has AST and ALT <3 × ULN which are not attributed to HBV infection
    3. on antiviral treatment, as clinically indicated
  20. Subjects with active Hepatitis C virus (HCV) infection (HCV antibody positive and HCV-RNA > the lower limit of detection). Subjects with a positive anti-HCV antibody are eligible only if PCR is negative for HCV RNA

  21. Subjects with active or latent tuberculosis

  22. Subjects with active and uncontrolled infections requiring IV antibiotic, antiviral, or antifungal treatment, such as severe pneumonia, bacteremia, sepsis, etc., within 1 week prior to first dose of study treatment. Subjects on stable oral antimicrobials with no clinical or laboratory evidence of active infection are eligible

  23. Received an investigational drug within 2 weeks prior to first dose of study treatment.

  24. Subjects who are pregnant, breastfeeding, or planning to become pregnant during the study

  25. Prior treatment with a topoisomerase inhibitor-based antibody-drug conjugate (ADC.)

  26. Previous history of significant gastrointestinal conditions, including Grade 3 or higher diarrhea, colitis, gastrointestinal bleeding and history of major gastrointestinal surgeries

28. Progressed on more than 2 different lines of systemic cytotoxic therapies; patients with 3 prior lines of systemic cytotoxic therapy or with prior allogeneic stem cell transplant may be enrolled upon consultation and approval from the sponsor

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위화되지 않음
  • 중재 모델: 순차적 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Experimental: Cohort A BL-M11D1 administered Days 1, 8 and 15 in 28-day cycle

Cohort A: BL-M11D1 will be administered on Days 1, 8 and 15 by intravenous infusion every 28 days.

The study includes 2 parts:

Part 1 Dose escalation and Dose Finding

실험적: Experimental: Cohort B BL-M11D1 administered Days 1, 4 7 or 8 in 28-day cycle

Cohort B: BL-M11D1 will be administered on Days 1,4, 7 or 8 by intravenous infusion every 28 days.

The study includes 2 parts:

Part 1 Dose escalation and Dose Finding

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Participants with dose-limiting toxicities
기간: 1 Year

DLTs are defined as any of the following events that are not clearly due to the underlying disease, disease progression, or extraneous causes:

  • Any treatment-emergent adverse event (TEAE) of ≥ Grade 3 except those due to disease progression or extraneous cause
  • Any TEAE that leads to dose reduction or withdrawal Nonhematologic toxicities
  • Death
  • Hy's law cases
  • Grade ≥3 nonhematologic toxicities (with exceptions) Hematologic toxicity
  • Grade 4 thrombocytopenia or neutropenia lasting >42 days in the absence of persistent leukemia
  • Grade ≥3 platelet count decreased with clinically significant hemorrhage
1 Year
Participants with Serious Adverse Events (SAEs) and treatment-emergent adverse events (TEAEs)
기간: 1 Year

Measuring the number of patients with serious adverse events (SAEs) and treatment-emergent adverse events (TEAEs)

1 Year
To determine the minimum safe and effective dose (MSED), maximum tolerated dose (MTD) if reached, and maximum administered dose (MAD) of BL-M11D1 in AML
기간: 1 Year

Determine the highest BL-M11D1 dose level at which ≤33% subjects experience a DLT during the DLT evaluation period and highest BL-M11D1 dose administered in the event and MTD cannot be defined.

1 Year

2차 결과 측정

결과 측정
측정값 설명
기간
Cmax of BL-M11D1
기간: 1 Year

Calculate maximum (peak) observed concentration of BL-M11D1

1 Year
Tmax of BL-M11D1
기간: 1 Year

Calculate time of maximum observed concentration of BL-M1D1

1 Year
Tmax of free payload ED-04
기간: 1 Year

Calculate time of maximum observed concentration of free payload ED-04

1 Year
Cmax of free payload ED-04
기간: 1 Year

Calculate maximum (peak) observed concentration of free payload ED-04

1 Year
AUC(0-8) of BL-M11D1
기간: 1 Year

Calculate area under the serum concentration-time curve of BL-M11D1 from time 0 to 8 hours

1 Year
AUC(0-8) of free payload ED-04
기간: 1 Year

Calculate area under the serum concentration-time curve of free payload ED-04 from time 0 to 8 hours

1 Year
AUC(last) of BL-BM11D1
기간: 1 Year

Calculate area under the serum concentration-time curve up of BL-M11D1 to the last quantifiable time

1 Year
AUC(last) of free payload ED-04
기간: 1 Year

Calculate area under the serum concentration-time curve up of free payload ED-04 to the last quantifiable time

1 Year
Tmax of anti-CD33 antibody
기간: 1 Year

Calculate time of maximum observed concentration of anti-CD33 antibody

1 Year
AUC (0-8) of anti-CD33 antibodies
기간: 1 Year

Calculate area under the serum concentration-time curve of anti-CD33 antibodies from time 0 to 8 hours

1 Year
AUC (last) anti-CD33 antibodies
기간: 1 Year

Calculate area under the serum concentration-time curve up of anti-CD33 antibodies to the last quantifiable time

1 Year
Overall Response Rate (ORR)
기간: 1 Year

To assess the clinical efficacy of BL-M11D1 as measured by ORR using RECIST criteria v 1.1

1 Year
Duration of response (DOR)
기간: 1 Year

To access the clinical efficacy of BL-M11D1 as measured by DOR using RECIST criteria 1.1

1 Year
Complete Remission (CR)
기간: 1 Year

To assess the anti-cancer activity of BL-M11D1 as measured by CR using the European LeukemiaNet (ELN) 2022 AML criteria.

1 Year
CR with partial hematologic recovery (CRh)
기간: 1 Year

To assess the anti-cancer activity of BL-M11D1 as measured by CR using the European LeukemiaNet (ELN) 2022 AML criteria.

1 Year
CR with incomplete hematologic recovery (CRi)
기간: 1 Year

To assess the anti-cancer activity of BL-M11D1 as measured by CR using the European LeukemiaNet (ELN) 2022 AML criteria.

1 Year
CR/CRi, CRs with or without measurable residual disease (MRD)
기간: 1 Year

To assess the anti-cancer activity of BL-M11D1 as measured by CR using the European LeukemiaNet (ELN) 2022 AML criteria.

1 Year
morphologic leukemia-free state (MLFS)
기간: 1 Year

To assess the anti-cancer activity of BL-M11D1 as measured by CR using the European LeukemiaNet (ELN) 2022 AML criteria.

1 Year
partial remission (PR)
기간: 1 Year

To assess the anti-cancer activity of BL-M11D1 as measured by CR using the European LeukemiaNet (ELN) 2022 AML criteria.

1 Year

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 연구 책임자: Olu Lawson, SystImmune Inc.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2024년 12월 19일

기본 완료 (실제)

2026년 9월 16일

연구 완료 (실제)

2026년 9월 16일

연구 등록 날짜

최초 제출

2024년 11월 27일

QC 기준을 충족하는 최초 제출

2024년 11월 27일

처음 게시됨 (실제)

2024년 12월 3일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 24일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 21일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • BL-M11D1-HM-101

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .